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Acid  stable  trypsin  inhibitor  having  the  same  antigenicity  as  urinary  trypsin 
inhibitor  was  first  identified  in  the  bile  of  patients  with  rn~i~~t  tumors  (biliary 
tract  carcinoma  or  pancreas  head  carcinoma)  and  gallstones.  Bile  trypsin  inhibitor 
from  malignant  tumor  patients  was  partially  purified  by  DEAE  cellulose  ion 
exchange  column  chromatography.  Two  molecular  forms  of  the  inhibitor  were 
identified.  The  main  form  had  a  molecular  weight  of  about  86000  and  the  minor 
one  a  molecular  weight  of  31000  as determined  by  gel  filtration.  Using  isoelectric 
focussing,  the  larger  molecular  form  gave  a pZ  value  of  2.0 and  the  smaller  form,  a 
pZ  value  of  5.1. The  isolated  larger  form  migrated  on  the  slightiy  cationic  side  of 
human  serum  albumin  by  analytical  poiya~~la~de  gel electrophoresis.  The  larger 
form  reacted  and  fused  with  anti-urinary  trypsin  inhibitor  serum  and  strongly 
inhibited  trypsin,  partially  inhibited  chymotrypsin  and  plasmin,  but  did  not  inhibit 
urokinase.  The  clinical  significance  of  acid  stable%ypsin  inhibitor  is discussed. 
Since  Muller  first  reported  an  acid  stable  trypsin  inhibitor  in  human  urine  in 
1908  [l],  many  investigators  have  described  increased  levels  of  urinary  trypsin 
inhibitor  in  various  physiological  and  pathological  states  {2-lo].  Faarvang  found 
that  the  excretion  of  urinary  trypsin  inhibitor  was  related  to  17-keto  steroid  [4,9]. 
Acid  stable  trypsin  inhibitors  having  the  same  antigenicity  as  urinary  trypsin 
inhibitor  were  also  reported  in human  plasma  by  Proksch  et al [ll],  Hochstrasser  et 
al [12], Maehara  et  al [13], and  Maruyama  et  al [14]. 
The  origin  of  urinary  trypsin  inhibitor  was considered  to  be  plasma  protein,  for 
example,  inter-cw-trypsin inhibitor  [11,12]. However,  some  researchers  have  disagreed 
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with  this conclusion  [14-161.  In  1984, we demonstrated  a marked  increase  in plasma 
acid  stable  trypsin  inhibitor  in  hemodialysis  patients  who  were  anuric  1141. It  was 
assumed  that  in normal  subjects,  plasma  acid  stable  trypsin  inhibitor  was  excreted 
into  the  urine  as  urinary  trypsin  inhibitor.  The  possibility  exists  that  plasma  acid 
stable  trypsin  inhibitor  might  be  excreted  via other  excretory  pathways,  such  as the 
biliary  tract. 
In  the  present  study,  we  first  demonstrated  the  presence  of  acid  stable  trypsin 
inhibitor  in bile,  and  succeeded  in preparing  and  characterizing  this  inhibitor. 
Materials and methods 
The  following  substances  were  used:  trypsin  (73%  active  by  p-nitrophenyl-p’- 
guanidinobenzoate  titration),  chymotrypsin  (Sigma  Chemical  Co.,  St.  Louis,  MO, 
USA,  type  I),  casein  (Hammarsten,  Wako  Pure  Chemical  Industry  Co.,  Osaka, 
Japan),  Sephadex  G-100  (Pharmacia  Fine  Chemicals,  Uppsala,  Sweden),  DEAE 
cellulose  (Seikagaku  Kogyo  Co.,  Tokyo,  Japan),  bovine  serum  albumin  (Armour 
Ph~aceutical  Co.,  USA),  egg albumin  (Boeh~nger-Man~eim,  M~~eirn,  FRG), 
chymot~sinogen  A (Sigma  Chemical  Co.,  type  II),  rabbit  antisera  against  human 
qplasmin  inhibitor  (Mochida  Pharmaceutical  Co.,  Tokyo,  Japan),  inter-a-trypsin 
inhibitor,  a,-macroglobulin,  a,-antitrypsin  (Behringwerke,  Marburg,  FRG),  plasmin 
(Green  Cross  Corp.,  Osaka,  Japan),  and  urokinase  (Otsuka  Chemical  Pharm., 
Tokyo,  Japan).  Native  urinary  trypsin  inhibitor  (1551  U/mg)  and  its  antiserum 
were prepared  as described  previously  [17--191. Bile, plasma,  and  urine  samples  were 
obtained  from  6 patients  with  malignant  tumors  and  9 patients  with  gallstones.  The 
bile  samples  in  patients  with  malignant  tumors  were  taken  from  a  percutaneous 
transhepatic  cholangial  drainage  tube  which  was  located  in  an  upper  position 
relative  to the  malignant  tumor,  before  or during  chemotherapy.  The  bile samples  in 
patients  with  gallstones  were  obtained  by  direct  puncture  of  the  gallbladder  under 
operation.  All  subjects  had  normal  renal  function  and  patients  with  m~ign~t 
tumors  were  found  clinically  not  to  have  metastatis  to  the  liver.  The  samples  were 
mixed  with  30%  perchloric  acid  and  casein,  the  final  concentrations  being  6% 
(vol/vol)  and  1% (g/vol),  respectively.  After  standing  for  1 h at room  temperature, 
the  mixture  was centrifuged  at  12000  X g  for  30 min  at  4OC and  then  filtered  with 
Whatman  No.  1 filter  paper.  The  eluate  was dialyzed  against  a sufficient  volume  of 
saline  followed  by  l/IS  mol/l  phosphate  buffer  saline,  pH  7.4, for  1 day  at  4°C. 
Assay  methods for  bile trypin  inhibitor  activity  and protein  concentration 
Trypsin  inhibitor  activity  and  protein  concentration  were  assayed  as  described 
previously  [20,21j. One  unit  of bile  trypsin  inhibitor  was defined  as the  amount  that 
in~bited  1 @g trypsin  (commercial  source). 
The  amidase  activities  of  trypsin,  chymot~sin,  plasmin,  and  urokinase  were 
estimated  calorimetrically  by  the  initial  rate  method  using  5 x  lop4  mol/l  BZ-L- 
Arg-pNA,  Bz-L-Tyr-pNA,  H-D-Val-Leu-Lys-pNA,  and  pyro-Glu-Gly-Arg-pNA  as 
substrates,  respectively. 93 
Isolation  of bile trypsin inhibitor 
The  acid  treated  bile  of  the  patients  with  malignant  tumor  was  dialyzed  against 
50  mmol/l  Tris  buffer,  pH  7.4,  for  24  h  at  4OC. This  dialyzed  sample  (950  ml; 
i~bito~  activity,  3.7 U/ml;  spec  act,  370.0  U/mg)  was  applied  to  a  DEAE-cel- 
lulose  ion  exchange  column.  Elution  was  performed  with  a  linear  salt  gradient 
between  O-l  mol/l  NaCl. 
The  active  fractions  obtained  were  lyophilized  and  dissolved  in  2.5  ml  of  0.1 
mol/l  phosphate  buffer  containing  0.2  mol/l  NaCl,  pH  7.4.  This  solution  was 
applied  to  a  Sephadex  G-100  column. 
Isoelectric  focussing  (IEF)  was performed  by  Vesterberg  and  Svensson’s  method 
1221 using  carrier  ampholite  of  pH  3.5-10.  The  column  (LKB  8100,  110  ml)  was 
maintained  at  3-4°C  and  the  potential  at  900 V for  37 h. 
Characterization  of bile trypsin inhibitor 
Double  i~unodiffusion  was  performed  by  Ouchterlony’s  method  [23]  with 
rabbit  antisera  (as mentioned  above).  The  reaction  was developed  overnight  at room 
temperature.  The  gel concentration  in veronal  buffer  (I  = 0.07, pH  =  8.6) was 1.0%. 
Analytical  polyacrylamide  gel  electrophoresis  was  carried  out  by  Summaria’s 
method  [24]. 
Results 
No  significant  difference  was  observed  in  the  bile  trypsin  inhibitor  and  plasma 
acid  stable  trypsin  inhibitor  activities  between  the  two groups  of patients.  However, 
the  urinary  trypsin  inhibitor  activity  of  the  patients  with  malignant  tumors  (96.4 f 
19.3  U/ml,  n = 6)  was  much  higher  than  that  of  the  patients  with  gallstones 
(7.4 f  3.8 U/ml,  n = 9). 
As  shown  in  Fig.  1,  the  active  fractions  could  be  eluted  with  a  salt  gradient 
between  0.14-0.71  mol/l  of  NaCl  (fractions  Nos.  9-18).  The  inhibitory  activity  of 
the collected  active  fractions  was 11.8 U/ml  and  the spec  act was 655.0 U/mg. 
As  shown  in  Fig.  2,  the  molecular  weights  of  the  two  active  peaks  estimated 
roughly  from  the  standard  proteins  were  86000  and  31000,  respectively.  The  larger 
molecular  form  (fractions  Nos.  19-26)  and  77.0  U/ml  of  in~bito~  activity,  and  a 
spec  act  of  2264.7  U/mg.  The  collected  smaller  molecular  form  (fractions  Nos. 
31-33)  had  activities  of 28.3 U/ml  and  1225.0  U/mg,  respectively. 
1540  U larger  molecular  bile  trypsin  inhibitor  dissolved  in 2.5 ml of  50% sucrose 
containing  0.1% ampholite  was applied  to the  IEF  column.  As shown  in Fig. 3A, the 
main  active  peak  eluted  was  at  pf  = 2.0.  The  inhibitory  activity  of  the  collected 
main  active  fractions  (fractions  Nos.  3-6)  was  40.7  U/ml,  and  the  spec  act  was 
2 907.1  U/mg.  2600 U main  fraction  obtained  by  IEF  was collected  and  pooled  for 
the  purposes  of  characterization.  216  U  smaller  molecular  weight  bile  trypsin 
inhibitor  was applied  to  the  IEF  column  as described  above.  As shown  in  Fig.  3B, 
the  main  active  peak  was at  pl  =  5.1. The  inhibitory  activity  of  the  collected  active 
fractions  {fractions  Nos.  10-12)  was  3.8 U/ml,  and  the  spec  act  was  950.0  U/mg. 
The  recovery  and  purity  at each  step arc  summarized  in Table  I. 94 
I  ’ 
10  al 
Fraction  No.  (30 mlifradlonl 
1 
30 
Fig.  1. Ion  exchange  cohmm  chromato~aphy  on  MAE-cellulose  column,  3 X 8 cm;  elution  buffer,  50 
mmol/l  Tris  buffer,  pH  7.4; gradiated  from  fraction  No.  7 (vertical  arrow);  protein  concentration;  0,  46 
inhibition;  0,  NaCl  molarity;  -  -  -.  The  fractions  indicated  by  the  bar  were pooled.  % inhibition  of 
bile  trypsin  inhibitor  was  obtained  by  m~rement  of  the  abihty  of  each  fraction  to  reduce  the 
amidoiytic  activity  of  trypsin  by  the  end  point  method.  The  assay  system  was as follows.  50 pf  of  l/15 
md/l  phosphate  buffer  (as  control)  or  each  fraction  and  0.5 pg  trypsin  were  mixed  and  incubated  at 
37YI  for  5 min.  50 ,ctl of  Bz-t-Arg-pNA  was then  added  and  the  mixture  was incubated  at 37*C  for  30 
min.  20 pl  of  50% acetic  acid  was  added  to this  mixture  and  the  absorbance  at  o.d.,,  was  measured. 
Inhibitory  activity  is expressed  as % inhibition  against  control  trypsin  activity. 
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Fig. 2. Gel  filtration  on  Sephadex  G-100. Column,  2 X48  cm;  elution  buffer,  0.1 mol/I  phosphate  buffer 
containing  0.2 mol/l  NaCl,  pH  7.4; inhibitory  activity;  0,  protein  concentration;  0,  BSA, bovine  serum 
~bu~n  (mol  wt.  67000);  EA,  egg  albumin  (mol  wt.  45000);  CTG-A,  chymotrypsinogen  A  fmol  wt. 
25000). The  fractions  indicated  by  the  bar  were pooled. 95 
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Fig.  3.  Isoelectric  focussing  patterns.  A,  Isoelectric  pattern  of  larger  molecular  weight  bile  trypsin 
inhibitor;  B,  that  of  smaller  molecular  weight  bile  trypsin  inhibitor.  Inhibitory  activity  0,  protein 
concentration;  0,  pH  gradient;  -  -  -.  The  fractions  indicated  by  the  bar  were pooled. 
Both  the  larger  and  smaller  molecular  weight  bile  trypsin  inhibitors  obtained  by 
IEF  reacted  and  showed  a  single  precipitin  line  like  highly  purified  native  urinary 
trypsin  inhibitor  and  acid  treated  plasma  against  rabbit  anti-urinary  trypsin  inhibi- 
tor  serum.  On  the  other  hand,  neither  of  the  inhibitors  reacted  with  other  well 
known  antisera. 
TABLE  I 
Purification  of  larger  molecular  weight  bile  trypsin  inhibitor 
Fraction 
Acid  treatment 
DEAE-celiuiose 
Gel  filtration 
Isoelectric 
focussing 
Total  activity  BTI activity 
W  (U/n@ 
3515.0  3.7 
2 596.0  11.8 
1540.0  77.0 
508.7  40.7 
Spec act  Yield  Degree  of 
@J/mg)  CQ  purification 
370.0  100.0  1.00 
655.0  73.9  1.77 
2 264.7  43.8  6.12 
2907.1  14.5  7.86 96 
TABLE  11 
Inhibitory  spectrum  of  larger  molecular  weight  bile  trypsin  inhibitor 
Enzyme  Necessary  protein 
for  50%  inhibition  (pg) 
Bile  trypsin  inhibitor 
Trypsin  10  gg  2.8 
Chymotrypsin  10  Pg  15.0 
Plasmin  0.1  casein  U  21.0 
Urokinase  10  IU  n.i.  a 
’  n.i.,  No  inhibition  when  less  than  100  cg  of  purified  larger  molecular  weight  bile  trypsin  inhibitor  was 
used. 
After  analytical  polyacrylamide  gel  electrophoresis  of  the  larger  molecular  weight 
bile  trypsin  inhibitor  obtained  by  IEF,  almost  no  protein  band  was  stained  with 
Amido  black  or  silver  (Bio  Rad  Labs.  NJ,  USA),  but  bile  trypsin  inhibitor  activity 
could  be  detected  by  gel  strip  elution.  With  this  method,  there  were  at  least  three 
active  forms  of  which  the  main  active  peak  migrated  on  the  slightly  cationic  side  of 
human  ‘serum  albumin. 
Larger  molecular  form  bile  trypsin  inhibitor  was  confirmed  to  be  relatively  stable 
at  various  pHs  (pH  1-12)  and  temperatures  (0-100°C),  like  native  urinary  trypsin 
inhibitor. 
Preincubation  time  had  no  effect  on  the  larger  molecular  weight  bile  trypsin 
inhibitor. 
As  shown  in  Table  II  bile  trypsin  inhibitor  was  found  to  inhibit  strongly  trypsin, 
and  chymotrypsin  and  plasmin  to  a lesser  extent,  but  exerted  no  inhibitory  effect  on 
urokinase. 
Discussion 
In  1984,  we  reported  that  plasma  acid  stable  trypsin  inhibitor  was  markedly 
increased  in  hemodialysis  patients  [14].  Although  such  inhibitor  (molecular  weight 
70000-80000  by  gel  filtration)  cannot  be  removed  by  hemodialysis,  its  activity  was 
lower  than  our  expectations.  This  suggested  that  plasma  acid  stable  trypsin  inhibitor 
might  have  another  excretory  pathway  in  addition  to  that  via  the  urine. 
In  the  present  study,  we  first  demonstrated  the  presence  of  acid  stable  trypsin 
inhibitor  in  bile.  This  inhibitor  showed  the  same  antigenicity  as  urinary  trypsin 
inhibitor  as  confirmed  by  double  immunodiffusion.  The  presence  of  bile  trypsin 
inhibitor  implies  that  plasma  acid  stable  trypsin  inhibitor  might  be  excreted  in  the 
bile  as  well  as  in  the  urine.  We  suggest  that  bile  trypsin  inhibitor  may  be  one  of  the 
important  factors  reflecting  the  metabolism  and  excretion  of  plasma  acid  stable 
trypsin  inhibitor. 
We  found  previously  that  the  native  urinary  trypsin  inhibitor  (molecular  weight 
67000,  pl  2.0)  was  readily  transformed  to  many  active  fragments  under  various 91 
conditions  [20,25]. Larger  molecular  weight  bile  trypsin  inhibitor  also  showed  some 
active  fragments  by  IEF  and  analytical  polyacrylamide  gel  electrophoresis  like 
urinary  trypsin  inhibitor  (Fig.  3A).  These  observations  indicate  that  bile  trypsin 
inhibitor  may  also  be  susceptible  to  enzymatic  modification.  Larger  molecular 
weight  bile  trypsin  inhibitor  was  broadly  equivalent  to  urinary  trypsin  inhibitor  in 
its  molecular  weight,  pZ and  certain  other  properties  (stability,  inhibitory  spectrum 
and  transformation  to  active  fragments)  [17,18,20,25].  However,  it  exerted  an 
inhibitory  effect  on  trypsin  without  preincubation,  in  contrast  to  urinary  trypsin 
inhibitor  [18,20]. These  results  suggest  that  the  affinity  of  bile  trypsin  inhibitor  to 
trypsin  may  be  higher  than  that  of  urinary  trypsin  inhibitor.  Bile  trypsin  inhibitor 
might  be  more  effective  than  urinary  trypsin  inhibitor  in  vivo.  For  example,  when 
bile  flows  backward  to  the  pancreatic  duct,  bile  trypsin  inhibitor  could  inhibit 
trypsin  to  prevent  pancreatic  disorders.  The  relationship  between  bile  trypsin 
inhibitor  and  the  mechanism  of  occurrence  of  pancreatitis  is  thus  of  considerable 
interest. 
Some  researchers  have  recently  suggested  that  acid  stable  trypsin  inhibitor  may 
be  produced  by  malignant  tumor  tissues  [10,26,27].  In  the  present  study,  there  was 
almost  no difference  in plasma  and  bile trypsin  inhibitors  between  the  two groups  of 
patients,  unlike  urinary  trypsin  inhibitor.  It  is  thought  that  the  acid  stable  trypsin 
inhibitor  produced  by  malignant  tumors  may  have  been  mainly  and  immediately 
excreted  in the  urine,  in so far  as renal  function  was not  disturbed.  Measurement  of 
urinary  trypsin  inhibitor  activity  may  thus  be  useful  in  the  differential  diagnosis  of 
gallstones  and  malignant  tumors. 
Various  problems  related  to  the  clinical  and  basic  significance  of  bile  trypsin 
inhibitor  still  remain,  and  further  detailed  studies  are  clearly  required. 
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